Compare IVVD & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVVD | BAFN |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 40.6M |
| IPO Year | 2021 | N/A |
| Metric | IVVD | BAFN |
|---|---|---|
| Price | $2.39 | $7.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 12.0M | 5.6K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,039,000.00 | ★ $58,931,000.00 |
| Revenue This Year | $103.88 | N/A |
| Revenue Next Year | $171.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | N/A |
| 52 Week Low | $0.35 | $6.40 |
| 52 Week High | $3.07 | $19.75 |
| Indicator | IVVD | BAFN |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 36.16 |
| Support Level | $2.15 | $8.05 |
| Resistance Level | $2.60 | $8.07 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 48.36 | 11.50 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.